Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper

Br J Dermatol. 2024 Feb 16;190(3):340-342. doi: 10.1093/bjd/ljad433.

Authors

Brent J Doolan¹, John A McGrath¹, Jemima E Mellerio¹

Affiliation

¹ Genetic Skin Disease Group, St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.

PMID: 37936299
DOI: 10.1093/bjd/ljad433

No abstract available

MeSH terms

Epidermolysis Bullosa Dystrophica* / genetics
Epidermolysis Bullosa Dystrophica* / therapy
Epidermolysis Bullosa* / therapy
Genetic Therapy
Humans
Skin
Skin Abnormalities*